The gradual loss of muscle with age, a condition called sarcopenia, can increase the likelihood of dangerous falls and broken bones. Gerologix is developing small molecules to block the enzyme that causes sarcopenia, opening the possibility of a pharmaceutical therapy for muscle loss.
Gerologix’s molecules target the IDO-kynurenine pathway, a regulator of the body’s immune system. If tests prove the company’s molecule to be effective, Gerologix intends to explore their application to treat muscle loss related to other diseases, such as cancer and HIV.
Company website: Gerologix
Back to companies